Autologous Stem Cell and Non-Stem Cell Based Therapies Market Development Analysis Contributing Top Vendor Landscape and Economic Growth 2028
Autologous stem-cell transplantation (also known as autogeneic,
autogenic, or autogenous stem-cell transplantation or auto-SCT) is the
autologous transplantation of stem cells—which is, transplantation in which the
undifferentiated cells or stem cells (cells from which other types of cells
develop) are taken from a person, accumulated, and given back to the same
person later. Even though it is most often executed by means of hematopoietic
stem cells (antecedent of cells that forms blood) in hematopoietic stem cell
transplantation, in some cases cardiac cells are used productively to fix the
damages due to heart attacks. Stem cell transplantation can be of two types -
Autologous stem-cell transplantation and allogenic stem cell transplantation.
Increasing prevalence of
cancer will drive the overall autologous stem cell and non-stem cell based
therapies market
According to a report by National Cancer Institute, in 2016,
around 1,685,210 new cases of cancer were diagnosed in the U.S. alone. Moreover,
it was also noted that around 595,690 people died from the disease in the same
year. Autologous stem cell and non-stem cell based therapies is likely to
become one of the preferred treatment for cancer. As the prevalence of cancer
is rising at a considerable rate, the market is likely to grow during the
forecast period.
North America, followed by Europe accounted for the major share of
the autologous stem cell and non-stem cell based therapies market. This is due
to minimization of risks related with the treatment. Moreover, the demand for
these treatments is high due to their ability to cure a significant number of
infectious diseases. Autologous stem cell and non-stem cell based therapies do
not need an outside donor; therefore the treatment is less infectious and
convenient. These factors are likely to boost the growth of the market in North
America. However, Asia Pacific is expected to show the maximum growth in
the forecast period. The demand in this region will be led by countries such as
China, India, Malaysia, and Vietnam. The demand is likely to grow as autologous
stem cell and non-stem cell based therapies aid in the efficient management of
cardiovascular diseases as well.
Comments
Post a Comment